<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793624</url>
  </required_header>
  <id_info>
    <org_study_id>1222.13</org_study_id>
    <secondary_id>2008-001933-84</secondary_id>
    <nct_id>NCT00793624</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the long-term efficacy and safety of once
      daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat®
      inhaler, in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1 Response at Week 24</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 24 Weeks</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined Analysis</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>This outcome measure describes the combined analysis of the trials NCT00793624 and NCT00796653. Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 12 Weeks</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 48 Weeks</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks for Combined Analysis</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations). This is a combined analysis of the data from NCT00793624 and NCT00796653 showing adjusted values using a MMRM model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 2</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 6</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 12</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 48</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 2</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 2.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 6</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 6.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 12</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 12.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 18</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 18.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 32</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 32.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 40</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 40.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 48</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 48.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 12 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 2</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 6</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 12</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 48</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 2</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 2.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 6</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 6.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 12</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 12.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 18</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 18.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 24</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 32</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 32.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 48</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 48.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 40</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 40.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 12 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow Rate (PEFR) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Weekly mean pre-dose morning and evening PEFR. Results are from non−MMRM ANCOVA models by week, with Last observation carried forward (LOCF) up to each week. Fixed effects include treatment, tiotropium, strata and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Mean number of puffs of rescue medication used per day (daytime/nighttime/total)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating (PGR) at 6 Weeks</measure>
    <time_frame>Week 6</time_frame>
    <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating (PGR) at 12 Weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating (PGR) at 24 Weeks</measure>
    <time_frame>Week 24</time_frame>
    <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating (PGR) at 48 Weeks</measure>
    <time_frame>Week 48</time_frame>
    <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 6 Weeks</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 12 Weeks</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 18 Weeks</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 32 Weeks</measure>
    <time_frame>Baseline, Week 32</time_frame>
    <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 40 Weeks</measure>
    <time_frame>Baseline, Week 40</time_frame>
    <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnea Index Focal Score at 48 Weeks</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation Leading to Hospitalization</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations</measure>
    <time_frame>Baseline to end of study at week 48 visit</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations Requiring Hospitalization</measure>
    <time_frame>Baseline to end of study at week 48 visit</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbations</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Plasma Concentrations</measure>
    <time_frame>within 2 hours before first drug administration and 10 minutes post-dose at week 6, 12 and 18</time_frame>
    <description>Absolute plasma concentrations of Olodaterol. Values presented are across visits and summarised into geometric means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Safety Parameters Related to Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Occurence of cardiac disorders and investigations related to treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">906</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol 12mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12mcg inhaled twice daily from the Aerolizer inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744)</intervention_name>
    <description>Comparison of low and high doses on efficacy and safety in COPD patients</description>
    <arm_group_label>Olodaterol (BI 1744) Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744)</intervention_name>
    <description>Comparison of low and high doses on efficacy and safety in COPD patients</description>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients</description>
    <arm_group_label>Formoterol 12mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for comparison Formoterolon safety and efficacy in COPD patients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients must have a diagnosis of chronic obstructive pulmonary disease and must
             meet the following spirometric criteria:post-bronchodilator FEV1&lt;80% of predicted
             normal (ECSC) and a post-bronchodilator FEV1/FVC &lt;70% at Visit 1

          2. Male or female patients, 40 years of age or older

          3. Patients must be current or ex-smokers with a smoking history of more than 10 pack
             years:

        Exclusion criteria:

          1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis; all patients with an SGOT &gt;x2 ULN, SGPT &gt;x2 ULN, bilirubin &gt;x2 ULN or
             creatinine &gt;x2 ULN

          2. Patients with a history of asthma and/or total blood eosinophil count greater than
             600/mm3

          3. Patients with thyrotoxicosis, paroxysmal tachycardia (&gt;100 beats per minute)

          4. Patients with a history of myocardial infarction within 1 year of screening visit,
             unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure
             within the past year, known active tuberculosis, a malignancy for which patient has
             undergone resection, radiation therapy or chemotherapy within last five years,
             life-threatening pulmonary obstruction, cystic fibrosis, clinically evident
             bronchiectasis, significant alcohol or drug abuse

          5. Patients who have undergone thoracotomy with pulmonary resection

          6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at
             unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of
             the equivalent of 10 mg of prednisone per day or 20 mg every other day.

          7. Patients who regularly use daytime oxygen therapy for more than one hour per day.

          8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior
             to the screening visit (Visit 1) or patients who are currently in a pulmonary
             rehabilitation program

          9. Pregnant or nursing women

         10. Women of childbearing potential not using two effective methods of birth control (one
             barrier and one non-barrier).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.13.2401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monte Grande</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Juiz de Fora</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Downsview</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1413 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Malbaie</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Point Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubrovnik</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beroun</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cesky Tesin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1511 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1514 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1509 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1508 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1510 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1512 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reinfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1507 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2806 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore-</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2810 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2807 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ludhiana, Punjab</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2809 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2812 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2811 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1705 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2705 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2706 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Batu Caves</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kota Kinabalu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.2301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aranjuez</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1806 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Els Hostalets de Balenyà</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vic (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boden</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.1902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.13.3603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2014</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects were randomized but not treated due to withdrawn consent and inability to perform spirometry prior to dosing.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P2">
          <title>Olodaterol (Olo) 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Olodaterol (Olo) 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P4">
          <title>Form 12 mcg</title>
          <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="227"/>
                <participants group_id="P3" count="225"/>
                <participants group_id="P4" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="191"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not described above</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B2">
          <title>Olo 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B3">
          <title>Olo 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B4">
          <title>Form 12 mcg</title>
          <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="225"/>
            <count group_id="B2" value="227"/>
            <count group_id="B3" value="225"/>
            <count group_id="B4" value="227"/>
            <count group_id="B5" value="904"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="8.4"/>
                    <measurement group_id="B2" value="63.7" spread="9.1"/>
                    <measurement group_id="B3" value="62.6" spread="8.8"/>
                    <measurement group_id="B4" value="64.8" spread="8.6"/>
                    <measurement group_id="B5" value="63.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tiotropium (Tio) Use Stratum</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-tiotropium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="169"/>
                    <measurement group_id="B5" value="673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiotropium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" spread="0.016"/>
                    <measurement group_id="O2" value="0.142" spread="0.015"/>
                    <measurement group_id="O3" value="0.156" spread="0.015"/>
                    <measurement group_id="O4" value="0.168" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.151</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.165</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.124</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.177</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.136</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response at Week 24</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 24</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.015"/>
                    <measurement group_id="O2" value="0.021" spread="0.015"/>
                    <measurement group_id="O3" value="0.028" spread="0.015"/>
                    <measurement group_id="O4" value="-0.002" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.085</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.044</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 24 Weeks</title>
        <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 24 Weeks</title>
          <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.046" spread="0.255"/>
                    <measurement group_id="O2" value="2.234" spread="0.240"/>
                    <measurement group_id="O3" value="2.068" spread="0.245"/>
                    <measurement group_id="O4" value="1.818" spread="0.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5843</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.188</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.343</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.485</ci_lower_limit>
            <ci_upper_limit>0.860</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9494</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.345</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.656</ci_lower_limit>
            <ci_upper_limit>0.699</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5099</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.288</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.346</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.908</ci_lower_limit>
            <ci_upper_limit>0.451</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks</title>
        <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks</title>
          <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.068" spread="1.038"/>
                    <measurement group_id="O2" value="38.627" spread="0.995"/>
                    <measurement group_id="O3" value="37.674" spread="0.998"/>
                    <measurement group_id="O4" value="40.116" spread="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0816</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.442</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.401</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.190</ci_lower_limit>
            <ci_upper_limit>0.307</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0155</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.394</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.400</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.141</ci_lower_limit>
            <ci_upper_limit>-0.648</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4954</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.952</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.396</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.691</ci_lower_limit>
            <ci_upper_limit>1.787</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 12 Weeks</title>
        <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 12 Weeks</title>
          <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.105" spread="1.027"/>
                    <measurement group_id="O2" value="39.320" spread="0.986"/>
                    <measurement group_id="O3" value="36.961" spread="0.989"/>
                    <measurement group_id="O4" value="40.351" spread="0.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0450</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.785</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.387</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.507</ci_lower_limit>
            <ci_upper_limit>-0.063</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.144</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.386</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.864</ci_lower_limit>
            <ci_upper_limit>-2.425</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2061</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.754</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.386</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.474</ci_lower_limit>
            <ci_upper_limit>0.966</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 48 Weeks</title>
        <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 48 Weeks</title>
          <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.415" spread="1.057"/>
                    <measurement group_id="O2" value="38.545" spread="1.000"/>
                    <measurement group_id="O3" value="36.850" spread="1.015"/>
                    <measurement group_id="O4" value="40.431" spread="1.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1878</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.871</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.419</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.655</ci_lower_limit>
            <ci_upper_limit>0.914</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0126</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.565</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.427</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.364</ci_lower_limit>
            <ci_upper_limit>-0.767</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9913</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.426</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.782</ci_lower_limit>
            <ci_upper_limit>2.814</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks for Combined Analysis</title>
        <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations). This is a combined analysis of the data from NCT00793624 and NCT00796653 showing adjusted values using a MMRM model.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full analysis sets (FAS) of the trials NCT00793624 and NCT00796653. FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks for Combined Analysis</title>
          <description>Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations). This is a combined analysis of the data from NCT00793624 and NCT00796653 showing adjusted values using a MMRM model.</description>
          <population>Full analysis sets (FAS) of the trials NCT00793624 and NCT00796653. FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="416"/>
                <count group_id="O3" value="414"/>
                <count group_id="O4" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.639" spread="0.718"/>
                    <measurement group_id="O2" value="38.794" spread="0.693"/>
                    <measurement group_id="O3" value="38.205" spread="0.695"/>
                    <measurement group_id="O4" value="40.391" spread="0.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olo 5 mcg qd minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.846</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.972</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.751</ci_lower_limit>
            <ci_upper_limit>-0.940</ci_upper_limit>
            <estimate_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olo 10 mcg qd minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.434</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.973</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.343</ci_lower_limit>
            <ci_upper_limit>-1.525</ci_upper_limit>
            <estimate_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Form 10 mcg qd minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.248</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.976</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.161</ci_lower_limit>
            <ci_upper_limit>0.665</ci_upper_limit>
            <estimate_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 2</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.015"/>
                    <measurement group_id="O2" value="0.201" spread="0.015"/>
                    <measurement group_id="O3" value="0.181" spread="0.015"/>
                    <measurement group_id="O4" value="0.221" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.186</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.146</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.126</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.206</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 6</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.015"/>
                    <measurement group_id="O2" value="0.178" spread="0.015"/>
                    <measurement group_id="O3" value="0.161" spread="0.015"/>
                    <measurement group_id="O4" value="0.194" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.136</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.160</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 12</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.015"/>
                    <measurement group_id="O2" value="0.176" spread="0.015"/>
                    <measurement group_id="O3" value="0.167" spread="0.015"/>
                    <measurement group_id="O4" value="0.182" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.137</ci_lower_limit>
            <ci_upper_limit>0.219</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.170</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.129</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.185</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.144</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 48</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.016"/>
                    <measurement group_id="O2" value="0.122" spread="0.015"/>
                    <measurement group_id="O3" value="0.123" spread="0.015"/>
                    <measurement group_id="O4" value="0.149" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.145</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.146</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.105</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.214</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 2</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 2.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 2</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.015"/>
                    <measurement group_id="O2" value="0.068" spread="0.014"/>
                    <measurement group_id="O3" value="0.060" spread="0.014"/>
                    <measurement group_id="O4" value="0.061" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 6</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 6.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 6</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.015"/>
                    <measurement group_id="O2" value="0.049" spread="0.014"/>
                    <measurement group_id="O3" value="0.041" spread="0.014"/>
                    <measurement group_id="O4" value="0.042" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.117</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 12</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 12.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 12</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" spread="0.015"/>
                    <measurement group_id="O2" value="0.056" spread="0.014"/>
                    <measurement group_id="O3" value="0.048" spread="0.014"/>
                    <measurement group_id="O4" value="0.033" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 18</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 18.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 18</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.015"/>
                    <measurement group_id="O2" value="0.046" spread="0.014"/>
                    <measurement group_id="O3" value="0.026" spread="0.015"/>
                    <measurement group_id="O4" value="0.023" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0276</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0426</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.042</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 32</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 32.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 32</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.015"/>
                    <measurement group_id="O2" value="0.023" spread="0.015"/>
                    <measurement group_id="O3" value="0.026" spread="0.015"/>
                    <measurement group_id="O4" value="0.021" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0237</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0175</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.049</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0339</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 40</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 40.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 40</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.016"/>
                    <measurement group_id="O2" value="0.020" spread="0.015"/>
                    <measurement group_id="O3" value="0.017" spread="0.015"/>
                    <measurement group_id="O4" value="0.004" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0537</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.040</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0808</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2579</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 48</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 48.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 48</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.065" spread="0.015"/>
                    <measurement group_id="O2" value="0.003" spread="0.015"/>
                    <measurement group_id="O3" value="-0.009" spread="0.015"/>
                    <measurement group_id="O4" value="-0.006" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0069</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" spread="0.016"/>
                    <measurement group_id="O2" value="0.277" spread="0.016"/>
                    <measurement group_id="O3" value="0.250" spread="0.016"/>
                    <measurement group_id="O4" value="0.290" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.177</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.135</ci_lower_limit>
            <ci_upper_limit>0.220</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.190</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.148</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081" spread="0.016"/>
                    <measurement group_id="O2" value="0.248" spread="0.016"/>
                    <measurement group_id="O3" value="0.234" spread="0.016"/>
                    <measurement group_id="O4" value="0.264" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.124</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.152</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.109</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.182</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082" spread="0.016"/>
                    <measurement group_id="O2" value="0.247" spread="0.016"/>
                    <measurement group_id="O3" value="0.241" spread="0.016"/>
                    <measurement group_id="O4" value="0.256" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.165</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.122</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.159</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" spread="0.017"/>
                    <measurement group_id="O2" value="0.216" spread="0.016"/>
                    <measurement group_id="O3" value="0.225" spread="0.016"/>
                    <measurement group_id="O4" value="0.236" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.148</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.104</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.167</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.112</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.167</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.123</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.017"/>
                    <measurement group_id="O2" value="0.192" spread="0.016"/>
                    <measurement group_id="O3" value="0.193" spread="0.016"/>
                    <measurement group_id="O4" value="0.215" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.162</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.117</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 2</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" spread="0.028"/>
                    <measurement group_id="O2" value="0.299" spread="0.027"/>
                    <measurement group_id="O3" value="0.311" spread="0.027"/>
                    <measurement group_id="O4" value="0.383" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.223</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.149</ci_lower_limit>
            <ci_upper_limit>0.297</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.235</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>0.309</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.307</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.233</ci_lower_limit>
            <ci_upper_limit>0.381</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 6</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.028"/>
                    <measurement group_id="O2" value="0.252" spread="0.027"/>
                    <measurement group_id="O3" value="0.265" spread="0.027"/>
                    <measurement group_id="O4" value="0.326" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.236</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>0.310</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.249</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.175</ci_lower_limit>
            <ci_upper_limit>0.324</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.310</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.235</ci_lower_limit>
            <ci_upper_limit>0.384</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 12</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.028"/>
                    <measurement group_id="O2" value="0.233" spread="0.027"/>
                    <measurement group_id="O3" value="0.278" spread="0.027"/>
                    <measurement group_id="O4" value="0.300" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.135</ci_lower_limit>
            <ci_upper_limit>0.285</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.254</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.179</ci_lower_limit>
            <ci_upper_limit>0.329</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.276</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.201</ci_lower_limit>
            <ci_upper_limit>0.352</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.029"/>
                    <measurement group_id="O2" value="0.220" spread="0.027"/>
                    <measurement group_id="O3" value="0.252" spread="0.028"/>
                    <measurement group_id="O4" value="0.279" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.182</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.258</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.215</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.291</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.242</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.318</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 48</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.029"/>
                    <measurement group_id="O2" value="0.196" spread="0.028"/>
                    <measurement group_id="O3" value="0.219" spread="0.028"/>
                    <measurement group_id="O4" value="0.260" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.179</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.256</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.203</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.126</ci_lower_limit>
            <ci_upper_limit>0.280</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.243</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.320</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 2</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 2.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 2</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.042" spread="0.028"/>
                    <measurement group_id="O2" value="0.110" spread="0.027"/>
                    <measurement group_id="O3" value="0.119" spread="0.028"/>
                    <measurement group_id="O4" value="0.126" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0781</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0455</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0290</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.085</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 6</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 6.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 6</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.046" spread="0.029"/>
                    <measurement group_id="O2" value="0.065" spread="0.027"/>
                    <measurement group_id="O3" value="0.085" spread="0.028"/>
                    <measurement group_id="O4" value="0.090" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 12</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 12.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 12</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.029"/>
                    <measurement group_id="O2" value="0.079" spread="0.028"/>
                    <measurement group_id="O3" value="0.087" spread="0.028"/>
                    <measurement group_id="O4" value="0.068" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0136</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.173</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.105</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0294</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.163</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 18</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 18.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 18</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.029"/>
                    <measurement group_id="O2" value="0.066" spread="0.028"/>
                    <measurement group_id="O3" value="0.078" spread="0.028"/>
                    <measurement group_id="O4" value="0.063" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8674</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.071</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6487</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.060</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9267</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.074</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 24</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 24</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.029"/>
                    <measurement group_id="O2" value="0.038" spread="0.028"/>
                    <measurement group_id="O3" value="0.064" spread="0.028"/>
                    <measurement group_id="O4" value="0.001" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1603</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.134</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0399</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6328</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 32</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 32.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 32</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.030"/>
                    <measurement group_id="O2" value="0.080" spread="0.028"/>
                    <measurement group_id="O3" value="0.084" spread="0.028"/>
                    <measurement group_id="O4" value="0.077" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1270</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1076</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1492</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 48</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 48.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 48</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" spread="0.030"/>
                    <measurement group_id="O2" value="0.022" spread="0.028"/>
                    <measurement group_id="O3" value="-0.002" spread="0.029"/>
                    <measurement group_id="O4" value="0.006" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0385</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1420</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0965</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.147</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 40</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 40.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 40</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.030"/>
                    <measurement group_id="O2" value="0.087" spread="0.028"/>
                    <measurement group_id="O3" value="0.086" spread="0.028"/>
                    <measurement group_id="O4" value="0.052" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1394</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1532</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5511</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.055</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.268" spread="0.029"/>
                    <measurement group_id="O2" value="0.454" spread="0.028"/>
                    <measurement group_id="O3" value="0.474" spread="0.028"/>
                    <measurement group_id="O4" value="0.551" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.186</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.264</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.206</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.128</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.283</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.205</ci_lower_limit>
            <ci_upper_limit>0.361</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202" spread="0.029"/>
                    <measurement group_id="O2" value="0.411" spread="0.028"/>
                    <measurement group_id="O3" value="0.433" spread="0.029"/>
                    <measurement group_id="O4" value="0.467" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.131</ci_lower_limit>
            <ci_upper_limit>0.288</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.231</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.153</ci_lower_limit>
            <ci_upper_limit>0.310</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.187</ci_lower_limit>
            <ci_upper_limit>0.344</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.194" spread="0.030"/>
                    <measurement group_id="O2" value="0.382" spread="0.029"/>
                    <measurement group_id="O3" value="0.432" spread="0.029"/>
                    <measurement group_id="O4" value="0.450" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.188</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.267</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.238</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.159</ci_lower_limit>
            <ci_upper_limit>0.318</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.256</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.177</ci_lower_limit>
            <ci_upper_limit>0.336</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.207" spread="0.030"/>
                    <measurement group_id="O2" value="0.379" spread="0.029"/>
                    <measurement group_id="O3" value="0.414" spread="0.029"/>
                    <measurement group_id="O4" value="0.424" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.173</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.253</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.207</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.288</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.217</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.137</ci_lower_limit>
            <ci_upper_limit>0.298</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.193" spread="0.031"/>
                    <measurement group_id="O2" value="0.344" spread="0.029"/>
                    <measurement group_id="O3" value="0.371" spread="0.030"/>
                    <measurement group_id="O4" value="0.416" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.070</ci_lower_limit>
            <ci_upper_limit>0.231</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.259</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.223</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.141</ci_lower_limit>
            <ci_upper_limit>0.304</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow Rate (PEFR) at Week 24</title>
        <description>Weekly mean pre-dose morning and evening PEFR. Results are from non−MMRM ANCOVA models by week, with Last observation carried forward (LOCF) up to each week. Fixed effects include treatment, tiotropium, strata and baseline.</description>
        <time_frame>Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow Rate (PEFR) at Week 24</title>
          <description>Weekly mean pre-dose morning and evening PEFR. Results are from non−MMRM ANCOVA models by week, with Last observation carried forward (LOCF) up to each week. Fixed effects include treatment, tiotropium, strata and baseline.</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>morning PEFR (N=214, 212, 216, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.429" spread="3.392"/>
                    <measurement group_id="O2" value="211.496" spread="3.420"/>
                    <measurement group_id="O3" value="211.428" spread="3.379"/>
                    <measurement group_id="O4" value="214.070" spread="3.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>evening PEFR (N=215, 211, 215, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.256" spread="3.363"/>
                    <measurement group_id="O2" value="219.977" spread="3.408"/>
                    <measurement group_id="O3" value="220.727" spread="3.360"/>
                    <measurement group_id="O4" value="220.129" spread="3.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Weekly mean morning PEFR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.639</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.962</ci_lower_limit>
            <ci_upper_limit>24.173</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for Weekly mean morning PEFR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.999</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.611</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.949</ci_lower_limit>
            <ci_upper_limit>24.049</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison for Weekly mean morning PEFR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.642</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.601</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.610</ci_lower_limit>
            <ci_upper_limit>26.673</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Weekly mean evening PEFR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.721</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.606</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.680</ci_lower_limit>
            <ci_upper_limit>26.762</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for Weekly mean evening PEFR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.471</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.579</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.484</ci_lower_limit>
            <ci_upper_limit>27.458</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison for Weekly mean evening PEFR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.873</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.548</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.947</ci_lower_limit>
            <ci_upper_limit>26.799</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication at Week 24</title>
        <description>Mean number of puffs of rescue medication used per day (daytime/nighttime/total)</description>
        <time_frame>Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication at Week 24</title>
          <description>Mean number of puffs of rescue medication used per day (daytime/nighttime/total)</description>
          <population>FAS</population>
          <units>Number of puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.364" spread="0.097"/>
                    <measurement group_id="O2" value="0.961" spread="0.099"/>
                    <measurement group_id="O3" value="1.037" spread="0.097"/>
                    <measurement group_id="O4" value="1.217" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.051" spread="0.125"/>
                    <measurement group_id="O2" value="1.449" spread="0.126"/>
                    <measurement group_id="O3" value="1.471" spread="0.125"/>
                    <measurement group_id="O4" value="1.701" spread="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.390" spread="0.196"/>
                    <measurement group_id="O2" value="2.399" spread="0.198"/>
                    <measurement group_id="O3" value="2.488" spread="0.196"/>
                    <measurement group_id="O4" value="2.917" spread="0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean daytime rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.403</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.133</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.665</ci_lower_limit>
            <ci_upper_limit>-0.141</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean daytime rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0141</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.327</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.133</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.587</ci_lower_limit>
            <ci_upper_limit>-0.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean daytime rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2677</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.132</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.406</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean nighttime rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.602</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.171</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.939</ci_lower_limit>
            <ci_upper_limit>-0.266</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean nighttime rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.580</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.170</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.914</ci_lower_limit>
            <ci_upper_limit>-0.247</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean nighttime rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0391</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.350</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.169</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.683</ci_lower_limit>
            <ci_upper_limit>-0.018</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean daily (24h) rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.991</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.269</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.518</ci_lower_limit>
            <ci_upper_limit>-0.464</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean daily (24h) rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.902</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.267</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.426</ci_lower_limit>
            <ci_upper_limit>-0.378</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison for weekly mean daily (24h) rescue use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0758</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.473</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.266</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.994</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating (PGR) at 6 Weeks</title>
        <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 6</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating (PGR) at 6 Weeks</title>
          <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.1"/>
                    <measurement group_id="O2" value="3.0" spread="0.1"/>
                    <measurement group_id="O3" value="3.1" spread="0.1"/>
                    <measurement group_id="O4" value="3.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating (PGR) at 12 Weeks</title>
        <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating (PGR) at 12 Weeks</title>
          <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.1"/>
                    <measurement group_id="O2" value="3.0" spread="0.1"/>
                    <measurement group_id="O3" value="2.9" spread="0.1"/>
                    <measurement group_id="O4" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0121</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating (PGR) at 24 Weeks</title>
        <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating (PGR) at 24 Weeks</title>
          <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.1"/>
                    <measurement group_id="O2" value="2.9" spread="0.1"/>
                    <measurement group_id="O3" value="2.9" spread="0.1"/>
                    <measurement group_id="O4" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0320</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0447</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1332</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating (PGR) at 48 Weeks</title>
        <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 48</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating (PGR) at 48 Weeks</title>
          <description>Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.1"/>
                    <measurement group_id="O2" value="3.0" spread="0.1"/>
                    <measurement group_id="O3" value="2.9" spread="0.1"/>
                    <measurement group_id="O4" value="2.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4105</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0584</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 6 Weeks</title>
        <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 6 Weeks</title>
          <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.995" spread="0.248"/>
                    <measurement group_id="O2" value="1.566" spread="0.236"/>
                    <measurement group_id="O3" value="1.660" spread="0.240"/>
                    <measurement group_id="O4" value="1.753" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0882</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.571</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.335</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.085</ci_lower_limit>
            <ci_upper_limit>1.227</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0484</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.664</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.336</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>1.324</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0252</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.758</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.338</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>1.421</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 12 Weeks</title>
        <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 12 Weeks</title>
          <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.412" spread="0.252"/>
                    <measurement group_id="O2" value="1.792" spread="0.239"/>
                    <measurement group_id="O3" value="1.955" spread="0.242"/>
                    <measurement group_id="O4" value="1.805" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2625</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.381</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.340</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.285</ci_lower_limit>
            <ci_upper_limit>1.047</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1109</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.543</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.341</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.125</ci_lower_limit>
            <ci_upper_limit>1.211</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2507</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.394</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.343</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.278</ci_lower_limit>
            <ci_upper_limit>1.066</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 18 Weeks</title>
        <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 18</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 18 Weeks</title>
          <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.665" spread="0.254"/>
                    <measurement group_id="O2" value="1.897" spread="0.240"/>
                    <measurement group_id="O3" value="2.099" spread="0.244"/>
                    <measurement group_id="O4" value="1.689" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4895</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.232</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.342</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.439</ci_lower_limit>
            <ci_upper_limit>0.902</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2073</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.434</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.344</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.240</ci_lower_limit>
            <ci_upper_limit>1.107</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9462</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.345</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.653</ci_lower_limit>
            <ci_upper_limit>0.700</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 32 Weeks</title>
        <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 32</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 32 Weeks</title>
          <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.732" spread="0.257"/>
                    <measurement group_id="O2" value="1.898" spread="0.241"/>
                    <measurement group_id="O3" value="1.698" spread="0.247"/>
                    <measurement group_id="O4" value="1.966" spread="0.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6309</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.345</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.511</ci_lower_limit>
            <ci_upper_limit>0.842</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9227</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.034</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.348</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.717</ci_lower_limit>
            <ci_upper_limit>0.649</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5030</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.234</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.349</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.451</ci_lower_limit>
            <ci_upper_limit>0.919</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 40 Weeks</title>
        <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 40</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 40 Weeks</title>
          <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.952" spread="0.259"/>
                    <measurement group_id="O2" value="1.839" spread="0.241"/>
                    <measurement group_id="O3" value="1.887" spread="0.249"/>
                    <measurement group_id="O4" value="1.575" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7459</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.347</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.793</ci_lower_limit>
            <ci_upper_limit>0.568</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8534</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.351</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.753</ci_lower_limit>
            <ci_upper_limit>0.623</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5099</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.377</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.352</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.068</ci_lower_limit>
            <ci_upper_limit>0.314</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 48 Weeks</title>
        <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 48 Weeks</title>
          <description>Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.940" spread="0.259"/>
                    <measurement group_id="O2" value="2.035" spread="0.242"/>
                    <measurement group_id="O3" value="2.324" spread="0.250"/>
                    <measurement group_id="O4" value="2.047" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7850</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.095</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.348</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.587</ci_lower_limit>
            <ci_upper_limit>0.777</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2755</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.383</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.352</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.306</ci_lower_limit>
            <ci_upper_limit>1.073</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7618</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.107</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.353</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.584</ci_lower_limit>
            <ci_upper_limit>0.798</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - tiotropium use stratum</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Non-tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - non-tiotropium use stratum.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd (Tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg qd (Non-tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd (Tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O6">
            <title>Olo 10 mcg qd(Non-tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O7">
            <title>Form 12 mcg (Tiotropium)</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O8">
            <title>Form 12 mcg (Non-tiotropium)</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler - non-tiotropium stratum</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="167"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="167"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" lower_limit="70.0" upper_limit="254.0"/>
                    <measurement group_id="O2" value="268" lower_limit="149.0">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O3" value="136" lower_limit="74.0" upper_limit="255.0"/>
                    <measurement group_id="O4" value="189" lower_limit="115.0" upper_limit="262.0"/>
                    <measurement group_id="O5" value="134" lower_limit="61.0" upper_limit="200.0"/>
                    <measurement group_id="O6" value="209" lower_limit="109.0" upper_limit="290.0"/>
                    <measurement group_id="O7" value="223" lower_limit="115.0" upper_limit="280.0"/>
                    <measurement group_id="O8" value="310" lower_limit="207.0">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3424</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.162</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.843</ci_lower_limit>
            <ci_upper_limit>1.603</ci_upper_limit>
            <estimate_desc>Comparison of Olo 5 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3023</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.186</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.195</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.859</ci_lower_limit>
            <ci_upper_limit>1.636</ci_upper_limit>
            <estimate_desc>Comparison of Olo 10 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3589</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.854</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.150</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.605</ci_lower_limit>
            <ci_upper_limit>1.205</ci_upper_limit>
            <estimate_desc>Comparison of Form 12 mcg to placebo across stratum</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation Leading to Hospitalization</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - tiotropium use stratum</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Non-tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - non-tiotropium use stratum.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd (Tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg qd (Non-tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd (Tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O6">
            <title>Olo 10 mcg qd(Non-tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O7">
            <title>Form 12 mcg (Tiotropium)</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O8">
            <title>Form 12 mcg (Non-tiotropium)</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler - non-tiotropium stratum</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation Leading to Hospitalization</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="167"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="167"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O2" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O3" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O4" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O5" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O6" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O7" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O8" value="NA">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1910</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.818</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.841</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.734</ci_lower_limit>
            <ci_upper_limit>4.503</ci_upper_limit>
            <estimate_desc>Comparison of Olo 5 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2274</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.743</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.817</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.695</ci_lower_limit>
            <ci_upper_limit>4.369</ci_upper_limit>
            <estimate_desc>Comparison of Olo 10 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5538</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.346</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.664</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.512</ci_lower_limit>
            <ci_upper_limit>3.538</ci_upper_limit>
            <estimate_desc>Comparison of Form 12 mcg to placebo across stratum</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - tiotropium use stratum</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Non-tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - non-tiotropium use stratum.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd (Tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg qd (Non-tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd (Tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O6">
            <title>Olo 10 mcg qd(Non-tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O7">
            <title>Form 12 mcg (Tiotropium)</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O8">
            <title>Form 12 mcg (Non-tiotropium)</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler - non-tiotropium stratum</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="167"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="167"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" lower_limit="86.0" upper_limit="325.0"/>
                    <measurement group_id="O2" value="296" lower_limit="215.0">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O3" value="239" lower_limit="98.0" upper_limit="304.0"/>
                    <measurement group_id="O4" value="244" lower_limit="154.0">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O5" value="175" lower_limit="123.0" upper_limit="271.0"/>
                    <measurement group_id="O6" value="302" lower_limit="213.0">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O7" value="280" lower_limit="167.0">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                    <measurement group_id="O8" value="270" lower_limit="270.0">N/A indicates this statistic was not available due to the low number of events observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5577</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.101</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.195</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.778</ci_lower_limit>
            <ci_upper_limit>1.557</ci_upper_limit>
            <estimate_desc>Comparison of Olo 5 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9423</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.714</ci_lower_limit>
            <ci_upper_limit>1.448</ci_upper_limit>
            <estimate_desc>Comparison of Olo 10 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1097</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.735</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.143</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.502</ci_lower_limit>
            <ci_upper_limit>1.076</ci_upper_limit>
            <estimate_desc>Comparison of Form 12 mcg to placebo across stratum</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.</description>
        <time_frame>Baseline to end of study at week 48 visit</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>Number of COPD ex. per patient year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="225"/>
                <count group_id="O4" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5684" spread="0.0718"/>
                    <measurement group_id="O2" value="0.7117" spread="0.0793"/>
                    <measurement group_id="O3" value="0.6946" spread="0.0801"/>
                    <measurement group_id="O4" value="0.5098" spread="0.0649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1729</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.2521</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2064</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9060</ci_lower_limit>
            <ci_upper_limit>1.7304</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2297</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.2220</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8808</ci_lower_limit>
            <ci_upper_limit>1.6954</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5354</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>0.8968</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1575</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6353</ci_lower_limit>
            <ci_upper_limit>1.2659</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations Requiring Hospitalization</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.</description>
        <time_frame>Baseline to end of study at week 48 visit</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations Requiring Hospitalization</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>Number of COPD ex. per patient year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="225"/>
                <count group_id="O4" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0554" spread="0.0249"/>
                    <measurement group_id="O2" value="0.1043" spread="0.0378"/>
                    <measurement group_id="O3" value="0.1324" spread="0.0493"/>
                    <measurement group_id="O4" value="0.0570" spread="0.0227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2508</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.8821</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0358</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6391</ci_lower_limit>
            <ci_upper_limit>5.5430</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1135</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>2.3877</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3119</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8122</ci_lower_limit>
            <ci_upper_limit>7.0194</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9611</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.0289</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3268</ci_lower_limit>
            <ci_upper_limit>3.2395</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbations</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbations</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>Number of COPD ex. per patient year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="225"/>
                <count group_id="O4" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4765" spread="0.0645"/>
                    <measurement group_id="O2" value="0.5537" spread="0.0674"/>
                    <measurement group_id="O3" value="0.5114" spread="0.0654"/>
                    <measurement group_id="O4" value="0.3721" spread="0.0537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4002</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.1621</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2075</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8187</ci_lower_limit>
            <ci_upper_limit>1.6497</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6983</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.0733</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1957</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7503</ci_lower_limit>
            <ci_upper_limit>1.5352</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2033</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>0.7810</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1516</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.5336</ci_lower_limit>
            <ci_upper_limit>1.1433</ci_upper_limit>
            <estimate_desc>Form 12 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Plasma Concentrations</title>
        <description>Absolute plasma concentrations of Olodaterol. Values presented are across visits and summarised into geometric means.</description>
        <time_frame>within 2 hours before first drug administration and 10 minutes post-dose at week 6, 12 and 18</time_frame>
        <population>Pharmacokinetic set includes all patients in the treated set who had at least one valid olodaterol plasma concentration measurement after initial administration of study drug. This set is restricted to patients in either the Olodaterol 5 μg or 10 μg dose group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Plasma Concentrations</title>
          <description>Absolute plasma concentrations of Olodaterol. Values presented are across visits and summarised into geometric means.</description>
          <population>Pharmacokinetic set includes all patients in the treated set who had at least one valid olodaterol plasma concentration measurement after initial administration of study drug. This set is restricted to patients in either the Olodaterol 5 μg or 10 μg dose group.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.179" spread="60.300"/>
                    <measurement group_id="O3" value="7.246" spread="72.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Safety Parameters Related to Treatment</title>
        <description>Occurence of cardiac disorders and investigations related to treatment.</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Safety Parameters Related to Treatment</title>
          <description>Occurence of cardiac disorders and investigations related to treatment.</description>
          <population>Treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="225"/>
                <count group_id="O4" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrioventricular block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrioventricular block first degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bundle branch block right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram QT prolonged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram T wave inversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined Analysis</title>
        <description>This outcome measure describes the combined analysis of the trials NCT00793624 and NCT00796653. Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full analysis sets (FAS) of the trials NCT00793624 and NCT00796653. FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined Analysis</title>
          <description>This outcome measure describes the combined analysis of the trials NCT00793624 and NCT00796653. Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).</description>
          <population>Full analysis sets (FAS) of the trials NCT00793624 and NCT00796653. FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before 24 weeks for any of the co-primary efficacy variables.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="427"/>
                <count group_id="O4" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.471" spread="0.155"/>
                    <measurement group_id="O2" value="1.980" spread="0.175"/>
                    <measurement group_id="O3" value="1.996" spread="0.170"/>
                    <measurement group_id="O4" value="1.827" spread="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olo 5mcg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0270</p_value>
            <method>pattern mixture model</method>
            <method_desc>See Hogan, et. al. Hogan JW, Roy J, Korkontzelou C Tutorial in biostatistics:handling drop-out in longitudinal studies. Stat Med 23,1455–1497(2004)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.509</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.230</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.960</ci_upper_limit>
            <estimate_desc>Based on a pattern mixture model with four patterns based on time of dropout (i.e., day of last observed data)
1) day 43 or day 85, 2) day 127 or day 169, 3) day 225 or day 281, 4) day 337</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olo 10 mcg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0203</p_value>
            <p_value_desc>See Hogan, et. al. Hogan JW, Roy J, Korkontzelou C Tutorial in biostatistics:handling drop-out in longitudinal studies. Stat Med 23,1455–1497(2004)</p_value_desc>
            <method>pattern mixture model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.525</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.226</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.967</ci_upper_limit>
            <estimate_desc>Based on a pattern mixture model with four patterns based on time of dropout (i.e., day of last observed data)
1) day 43 or day 85, 2) day 127 or day 169, 3) day 225 or day 281, 4) day 337</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Form 12mcg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1166</p_value>
            <method>pattern mixture model</method>
            <method_desc>See Hogan, et. al. Hogan JW, Roy J, Korkontzelou C Tutorial in biostatistics:handling drop-out in longitudinal studies. Stat Med 23,1455–1497(2004)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.355</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.226</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.088</ci_lower_limit>
            <ci_upper_limit>0.799</ci_upper_limit>
            <estimate_desc>Based on a pattern mixture model with four patterns based on time of dropout (i.e., day of last observed data)
1) day 43 or day 85, 2) day 127 or day 169, 3) day 225 or day 281, 4) day 337</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Olodaterol (Olo) 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olodaterol (Olo) 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Form 12 mcg</title>
          <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Parophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pancreatic insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental care</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

